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Abstract
Educating our immune system via vaccination is an attractive approach to combat infectious 
diseases. Eliciting antigen specific cytotoxic T cells (CTLs), CD8+ effector T cells, is essential in 
controlling intracellular infectious diseases such as influenza (Flu), tuberculosis (TB), hepatitis, 
and HIV/AIDS, as well as tumors. However, vaccination utilizing subunit peptides to elicit a 
potent CD8+ T cell response with antigenic peptides is typically ineffective due to poor 
immunogenicity. Here we have engineered a reduction sensitive nanoparticle (NP) based subunit 
vaccine for intracellular delivery of an antigenic peptide and immunostimulatory adjuvant. We 
have co-conjugated an antigenic peptide (ovalbumin-derived CTL epitope [OVA257–264: 
SIINFEKL]) and an immunostimulatory adjuvant (CpG ODNs, TLR9 agonist) to PEG hydrogel 
NPs via a reduction sensitive linker. Bone-marrow derived dendritic cells (BMDCs) treated with 
the SIINFEKL conjugated NPs efficiently cross-presented the antigenic peptide via MHC-I 
surface receptor and induced proliferation of OT-I T cells. CpG ODN-conjugated NPs induced 
maturation of BMDCs as evidenced by the overexpression of CD80 and CD40 costimulatory 
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receptors. Moreover, codelivery of NP conjugated SIINFEKL and CpG ODN significantly 
increased the frequency of IFN-γ producing CD8+ effector T cells in mice (~6-fold improvement 
over soluble antigen and adjuvant). Furthermore, the NP subunit vaccine-induced effector T cells 
were able to kill up to 90% of the adoptively transferred antigenic peptide-loaded target cell. These 
results demonstrate that the reduction sensitive NP subunit vaccine elicits a potent CTL response 
and provide compelling evidence that this approach could be utilized to engineer particulate 
vaccines to deliver tumor or pathogen associated antigenic peptides to harness the immune system 
to fight against cancer and infectious diseases.
Graphical abstract
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1. INTRODUCTION
Vaccines are one of the major discoveries in modern medicine. Contributions include the 
almost complete elimination of polio, eradication of small pox, and a decrease by more than 
95% of the incidence of diseases such as diphtheria, tetanus, pertussis, measles, mumps, and 
rubella.1 Vaccines have substantially decreased morbidity and mortality related to infectious 
disease and increased the average life span in the twenty-first century.
Despite these successes, there is a clear need to develop vaccines against pathogens like 
human immunodeficiency virus (HIV) and hepatitis C virus (HCV) and diseases such as 
malaria, tuberculosis, and cancer. Effective, traditional vaccines utilize live or attenuated 
pathogens which pose safety concerns due to the administration of unnecessary components 
of pathogenic microorganisms.2
New-generation subunit vaccines offer a safer and more specific approach to generate 
immunity, in which very specific components of pathogenic organisms (e.g., bacterial coat 
proteins, peptides, carbohydrates, or lipids; immunogenic determinants) are administered to 
protect against disease. Clinical success of subunit vaccines includes the use of Fluvirin 
(trivalent subunit protein) and Influvac (inactivated purified surface antigens from influenza 
virus) against influenza, BioThrax (AVA-anthrax adsorbed vaccine, contains no whole cell 
or live bacteria) against anthrax, and Cervarix (contains a mixture of human papilloma virus 
protein antigens with adjuvants alum and monophosphoryl lipid-A) against cervical cancer 
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caused by HPV.3 Because of our improved understanding of the immune system, more 
specific and safer peptide epitopes are being designed based on recombinant technology and 
epitope focusing.4
Peptide antigens are easily synthesized, stored, and transported. Specific antigenic peptide 
epitopes can induce an antigen specific cytotoxic T cell (CTL) response, which is of the 
utmost importance in the elimination of intracellular pathogens, as well as cancer cells. 
Successful intracellular delivery of peptides to professional APCs (mostly dendritic cells 
[DCs]) and their cross-presentation to T cells elicit CTLs. For cross-presentation, APCs can 
process endocytosed antigens by either the classical (also cytosolic pathway) or vacuolar 
pathway. In the classical pathway, protein antigens are processed into 8 to 12 amino acid 
fragments by proteasomal degradation machinery in cytosol and loaded onto MHC-I 
molecules in the endoplasmic reticulum (ER) or phagosome by antigen processing 
machinery (APM). In the vacuolar pathway, degradation of pathogens/antigens and loading 
of peptide fragments to MHC-I occurs in the endosome.5 However, soluble peptides suffer 
from fast degradation half-life (from a few seconds to minutes depending on their length)6 
and low cellular uptake, resulting in poor cross-presentation by DCs and lower 
immunogenicity.
Many particulate subunit vaccine delivery systems such as liposomes, nanobeads, solid-lipid 
nanoparticles, polymeric nanoparticle and micelles, etc. have been investigated as a delivery 
vehicle to induce protection against HIV, influenza, and cancer.7 Particulate carrier systems 
can improve immunogenicity of antigens and adjuvants by mimicking the size, shape, and/or 
surface molecule organization of pathogens, in order to facilitate uptake by APCs.8 
Additionally they prevent enzymatic degradation of antigens/adjuvants, and facilitate their 
intracellular delivery by increasing their local resident time.9 Depending on their 
degradation mechanism, the antigen can be released into the late endosome/lysosome or into 
cytosol. By optimizing the polymeric material of the nanoparticulate carrier, release of 
antigen can be triggered by changes in an intracellular pH,10,11 slower degradation rate of 
biodegradable polymeric carrier,12–14 or enzyme mediated release of antigen such as 
endolysosomal lipases15 or α-chymotrypsin.16
Efficient activation of DCs as well as induction and proliferation of T cells also requires 
costimulatory signals which can be provided by delivering adjuvants.17 Codelivery of 
antigens with adjuvants using particulate carriers can further boost the immune 
response.18,19 Many immune stimulating agents such as alum, oil in water emulsions, 
various TLR/NLR agonists, etc. are being explored in clinical as well as preclinical studies 
as vaccine adjuvants.20 TLR agonists such as monophosphoryl lipid-A (MPL-A), CpG, 
resiquimod, poly I:C, etc. have been investigated in the development of particulate 
vaccines.4 Antigen and adjuvant can be encapsulated, adsorbed, or conjugated to NPs. Sarti 
et al. demonstrated induction of IgA titers via codelivery of encapsulated MPL-A and 
ovalbumin (OVA) through PLGA (poly(lactic-co-glycolic acid)) particles.21 De Titta et al. 
has shown generation of antigen specific CD8+ effector cells as well as memory cells in 
mice by delivering OVA protein and CpG conjugated particles via disulfide bond.22 
Reversible cleavage and release of vaccine component can be made possible intracellularly 
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by reduction of disulfide bond. Many others have also utilized disulfide linkers to design 
endosomal releasing nanovaccine carriers to induce in vivo CTL response.23–26
In this study, we have designed a PEG (polyethylene glycol) based PRINT (particle 
replication in nonwetting template) NP subunit vaccine to deliver a MHC-I epitope 
(SIINFEKL) of ovalbumin and a TLR-9 agonist, CpG oligonucleotide (ODN). PRINT offers 
the ability to mold biocompatible nanoparticles with complete control over particle size, 
shape, and chemical composition in a manner heretofore not possible with other particle 
technologies. High aspect ratio (80 × 80 × 320 nm, aspect ratio = 4) particles were chosen 
since the rod shape emulates known pathogens27 and increased aspect ratio is known to 
enhance cellular uptake.28 The antigenic peptide (CSIIN-FEKL) and adjuvant (CpG ODN) 
were surface conjugated to NPs through reduction sensitive linkers, taking advantage of the 
intracellular reducing environment to trigger their release. Two cleavable linkers were 
investigated, a short SPDP (succinimidyl 3-(2-pyridyldithio)propionate) linker, and long 
NHS-PEG(2k)-OPSS linker. SPDP has been widely used to conjugate amine groups to thiol 
groups for intracellular delivery of siRNA–polymer conjugates,29,30 aptamer toxins, aptamer 
virus capsid conjugates,31,32 delivery of siRNA or DNA,33–36 or delivery of model antigen 
ovalbumin via NPs.37–39 Though the NHS-PEG-OPSS linker has not been used as 
extensively in the literature, there is evidence to support the hypothesis that linker length is 
important. For example, Chen et al. showed higher immunostimulatory response with gold 
labeled CpG ODN by increasing the proximity of CpG ODN to gold nanoparticles.40 
Furthermore, Singh et al. were able to demonstrate the effect of linker length on gene 
silencing efficiency of siRNA conjugated to quantum dots.41 We therefore hypothesized that 
linker length would play a significant role in the accessibility of biomolecules to their 
appropriate receptors. Our work demonstrates the significant role that linker length plays in 
the development of particulate based subunit vaccines. Herein we report the formulation of 
highly uniform and monodisperse hydrogel PRINT NPs co-conjugated with SIINFEKL and 
CpG, that are successfully taken up and processed by BMDCs, resulting in their efficient 
maturation and leading to SIINFEKL cross-presentation and subsequent induction of potent 
antigen-specific T cell proliferation and cytotoxic activity.
2. MATERIALS AND METHODS
2.1. Materials
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoethyl methacrylate 
hydrochloride (AEM), diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide (TPO), thiol 
modified CpG 1826 (C6-S-S-C6-tccatgacgttcctgacgtt), dithiothreitol (DTT), sucrose, and 
DNase, RNase free sterile water were purchased from Sigma-Aldrich. Tetraethylene glycol 
monoacrylate (HP4A) was synthesized in house. Cysteine modified OVA257–264 
(CSIINFEKL) were purchased from Peptide 2.0. Trifluoroacetic acid, methanol, dimethyl 
sulfoxide (DMSO), PTFE (polytetrafluoroethylene) syringe filters (13 mm membrane, 0.22-
μm pore size), HPLC grade water, and acetonitrile were obtained from Fisher Scientific. 
Conventional filters (2 μm) were purchased from Agilent Technologies, and poly(vinyl 
alcohol) (Mw 2000) (PVOH) was purchased from Acros Organics. N-Succinimidyl 3-(2-
pyridyldithio)propionate (SPDP) was purchased from Thermo Scientific. Ortho-
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pyridyldisulfide-PEG-N-hydroxylsuccinimide ester (NHS-PEG (2k)-OPSS) was purchased 
from Creative PEGworks. PRINT molds (80 nm × 320 nm) were obtained from Liquidia 
Technologies. DNA grade NAP-10 columns were purchased from GE Healthcare. 
RPMI1640 medium, penicillin and streptomycin, L-glutamine, and fetal bovine serum (FBS) 
were all from Life Technologies.
2.2. Methods
2.2.1. PRINT Nanoparticle Fabrication—The PRINT particle fabrication process is 
described previously.42 Briefly, the preparticle solution was prepared by dissolving 3.5 
weight percent (wt/wt) of the various reactive monomers in isopropyl alcohol (IPA). The 
reactive monomers included a cure-site monomer (an oligomeric PEG with a nominal molar 
mass of 700 g/mol terminally functionalized on both end groups with an acryl or acryloxy 
functionality); a hydrophilic monomer used to make up the majority of the particle 
composition (tetraethylene glycol monoacrylae, HP4A); an amine containing monomer 
(aminoethyl methacrylate, AEM) which provides a chemical handle to conjugate various 
linkers and peptides; and a photoinitiator, TPO. Preparticle solution was composed of 69 wt 
% HP4A, 10 wt % PEG700DA, 20 wt % AEM, and 1 wt % TPO. Using a #3 Mayer rod, a 
thin film of preparticle solution was drawn onto corona-treated PET using roll-to-roll lab 
line (Liquidia Technologies) running at 12 feet per minute. The solvent was evaporated by 
heat guns. Then an 80 × 80 × 320 nm, cylinder shaped mold was laminated to delivery sheet 
and passed through nip (80 psi, 12 feet per minute). After delamination, filled mold were 
cured by passing through a UV LED lamp (λmax = 395 nm, 30 psi of N2, 12 feet per 
minute; Phoseon). Due to UV light initiated radical chain polymerization, monomers cross-
linked into polymers to form a hydrogel. After cross-linking the hydrogels inside the mold 
cavities, the filled mold was laminated against a PVA harvesting sheet and passed through a 
heated nip (140 °C, 80 psi, 12 feet per minute). Particles were removed from the mold by 
splitting the harvesting sheet from the mold. Particles were then harvested by dissolving a 
sacrificial harvesting layer of PVA into water (2 mL of water per 10 feet of harvesting 
sheet). Particle suspensions were passed through 2 μm filter to remove additional scum layer. 
To remove excess PVA, particles were spun down at 14,000 rpm (Eppendorf Thermomixer 
R) for 25 min, and resuspended into sterile water. This purification procedure was repeated 3 
times.
2.2.2. Thermogravimetric Analysis—Concentrations of particles were determined by 
thermogravimetric analysis (TGA) using TA Instrument’s Discovery TGA. Aluminum 
sample pans were tarred before loading the sample. 20 μL of the stock nanoparticle solution 
was loaded onto the pan. Samples suspended in water were heated at 30 °C/min to 130 °C, 
followed by a 10 min isotherm at 130 °C. All samples were then cooled at 30 °C/min to 
30 °C, followed by a 2 min isotherm at 30 °C.
2.2.3. Scanning Electron Microscopy—Particles were visualized by scanning electron 
microscopy (SEM) using a Hitachi S-4700 SEM. Prior to imaging, SEM samples were 
coated with 1.5 nm of gold–palladium alloy using a Cressington 108 auto sputter coater.
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2.2.4. Dynamic Light Scattering—Particle size and zeta potential (ZP) were measured 
in sterile water by dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern 
Instruments, Ltd.).
2.2.5. Conjugation of Linker to NPs—We utilized amine groups from AEM to 
conjugate cleavable linkers, SPDP and NHS-PEG(2k)OPSS. Theoretical numbers of –NH2 
groups contributed from 1 mg of nanoparticle suspension were calculated. Different molar 
ratios of linker to amine groups (such as 0.28, 0.55, and 2.30) were evaluated for the 
conjugation scheme (Table S1). For the optimized reaction scheme, particles were reacted 
with a 0.55 molar excess of linker, resulting in reacting 1 mg of NPs with 0.24 mg of SPDP 
or 6 mg of NHS-PEG-OPSS in 1 mL of 1× PBS + 0.1% PVA for 2 h. SPDP (or NHS-
PEG(2k)OPSS) was dissolved in DMF. The volume of DMF was kept constant at 160 μL 
regardless of different linker mass used. Total volume of reaction was 1 mL. NPs were 
continuously agitated for 2 h at 1400 rpm (Eppendorf Thermomixer R). After 2 h, 
unconjugated linker was removed from the pyridyldithiol decorated NPs via 2 centrifugation 
washes (Eppendorf Centrifuge 5417g) with sterile water. Efficiency of linker conjugation 
was evaluated by incubating 1 mg of NPs in 1 mL of DTT solution. Moles of DTT used was 
10 times higher than the moles of linkers added during the conjugation procedure. Due to 
disulfide exchange reaction, pyridine-2-thione is released from pyridyldithiol modified NPs, 
which can be detected by reading absorbance at 343 nm using Spectra Max M plate reader. 
Conjugation efficiency was determined by the following formula:
(1)
Conjugation efficiency of linkers was between 50% and 60%.
2.2.6. Conjugation of CSIINFEKL to NPs—Once NPs were modified with SPDP or 
NHS-PEG(2k)OPSS, they were spun down for 25 min at 14,000 rpm (Eppendorf Centrifuge 
5417g) and resuspended into 800 μL of sterile water. 1 mg/mL of cysteine labeled 
SIINFEKL (CSIINFEKL) solution was made in sterile water. 200 μL of this solution was 
mixed with 800 μL of NP suspension and incubated overnight. NPs were continuously 
agitated at 1400 rpm (Eppendorf Thermomixer R). The following day, NPs were spun down 
for 25 min at 14,000 rpm (Eppendorf Centrifuge 5417g), supernatant was collected, and NPs 
were resuspended in 1 mL of sterile water. To remove unbound peptide, NPs were washed in 
sterile water 2 times. Due to disulfide exchange with cysteine labeled peptide, pyridine-2-
thione is released from pyridyl dithiol modified NPs. By reading the absorption of 
pyridine-2-thione in the supernatant at 343 nm using the Spectra Max M plate reader, the 
amount of pyridine-2-thione released from NPs can be calculated and thus the amount of 
peptide conjugated was evaluated. Conjugation efficiency of peptide was evaluated as 
mentioned by eq 1. We found 60–70% conjugation efficiency of peptide to NPs.
2.2.7. Reduction and Purification of C6-S-S-C6 CpG 1826—CpG 1826 with 
phosphorothioate backbone was chosen because of slower in vivo degradation via nucleases 
as compared to CpG with phosphodiester.43 C6-S-S-C6 CpG 1826 was reduced with 100 
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mM DTT solution in sodium phosphate buffer of pH 8.0 and purified by gel filtration 
chromatography using Sephadex NAP-10 column. Unreduced CpG was kept for an hour in 
the presence of 100 mM DTT solution in sodium phosphate buffer of pH 8.0. Sephadex 
NAP-10 column (DNA grade) was equilibrated by flowing through 15 mL of sterile water 
(DNase, RNase free). After equilibration, 0.75 mL of sample was loaded to column and 
allowed to pass through completely. Reduced CpG was eluted by passing through 1.2 mL of 
water. Concentration of CpG was measured by evaluating absorption at 260 nm by using a 
NanoDrop 2000 spectrophotometer.
2.2.8. Conjugation of Thiol-CpG 1826 to NPs—Once NPs were modified with SPDP 
or NHS-PEG(2k)OPSS, NPs were spun down for 25 min at 14,000 rpm (Eppendorf 
Centrifuge 5417g) and resuspended in 800 μL of sterile water. 40 μg of thiol CpG 1826 was 
mixed with 1 mg of linker modified NPs and kept for 8 to 10 h. Total volume of reaction was 
1 mL. NPs were continuously agitated at 1400 rpm (Eppendorf Thermomixer R). Then NPs 
were spun down for 25 min at 14,000 rpm (Eppendorf Centrifuge 5417g) and resuspended in 
200 μL of 10× PBS. This washing procedure was repeated 3 times to remove adsorbed CpG. 
To evaluate conjugation of CpG, NPs were incubated in 100 mM DTT for 4 h. NPs were 
spun down, and supernatant was collected. Conjugation efficiency of CpG was evaluated as 
mentioned by eq 1. Evaluation of CpG was done by reading absorption at 260 nm using 
NanoDrop 2000 spectrophotometer. We found 70–80% conjugation efficiency of CpG to 
NPs.
2.2.9. Co-conjugation of CSIINFEKL and CpG ODN to NPs—CSIINFEKL peptide 
and CpG were co-conjugated in a 2 step process. For the co-conjugation process we used 
0.39 mg of SPDP or 12 mg of NHS-PEG(2k)OPSS. After modification with linkers, NPs 
were conjugated to CSIINFEKL by incubating 1 mg of NPs with 0.2 mg of CSIINFEKL. 
Unbound peptides were removed by washing NPs in sterile water 2 times. After the final 
wash, nanoparticles were resuspended in 900 mL of sterile water and 0.04 mg of reduced 
CpG was added and left to react for 8–10 h at 1400 rpm (Eppendorf Thermomix R). After 
co-conjugation, to evaluate peptide and adjuvant loading, CSIINFEKL and CpG were 
cleaved from NPs by incubating 1 mg of NPs with 100 mM DTT for 4 h. After 4 h, 
nanoparticles were spun down at 14,000 rpm (Eppendorf Centrifuge 5417g) for 25 min, and 
the supernatant was evaluated for released peptide and adjuvant through HPLC Agilent 1200 
series and NanoDrop 2000 spectrophotometer, respectively. Co-conjugation of adjuvant 
resulted in a reduction of final peptide loading to 50% conjugation efficiency, while CpG 
loading remained at approximately 50–60% conjugation efficiency.
2.2.10. Peptide Evaluation via HPLC—Reverse phase high performance liquid 
chromatography (HPLC) was run on an Agilent 1200 series HPLC system using an Agilent 
C18 column. A Waters 2695 Alliance module equipped with quaternary pump, mobile phase 
degasser, temperature controlled auto sampler, and column thermostat were used for HPLC 
analysis. The separation was carried out on a Zorbax C18(2) column (150 mm × 4.6 mm i.d., 
3 μm particle size, 100 Å pore size) from Phenomenex (Torrance, CA) at column 
temperature of 50 °C and sample temperature of 50 °C. Peptide was eluted using a mobile 
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phase gradient, which consists of two solutions: solution A, water (0.1% TFA, trifluoroacetic 
acid), and solution B, acetonitrile with 0.1% TFA. The gradient method is shown in Table 1.
Binary linear gradients started from a mixture of 100% A and 0% B from 0 to 5 min. From 5 
to 25 min B was increased gradually from 0% to 95%. Then, until 28 min the gradient was 
kept 5% for A and 95% for B. The mobile phase composition was then changed back to 
initial solvent mixture, and the column was equilibrated for 2 min before every subsequent 
run. The flow rate of the mobile phase was set to 2.0 mL/min. The samples for HPLC 
injections were prepared by cleaving off peptide in 100 mM DTT in sterile water. Peptides 
were detected via UV–vis detector at 210 nm, and concentration was determined by 
comparing area of peak with standard curve. Know amounts of peptides were dissolved with 
100 mM DTT in sterile water to prepare a standard curve.
2.2.11. Animals—Female C57BL/6 mice and OT-I TCR transgenic mice were purchased 
from Jackson Laboratory and used at age 6–12 weeks. All experiments involving mice were 
carried out in accordance with an animal use protocol approved by the University of North 
Carolina Animal Care and Use Committee.
2.2.12. Preparation of Single Cell Culture from Mouse Spleens—Spleens were 
harvested from euthanized mice aseptically. Individual spleens were mechanically 
dissociated with the back of the sterile syringe plunger through a 100 μm cell strainer into 
RPMI 1640 medium. Red blood cells were lysed by ACK buffer. Cells were then 
resuspended in R-10 medium (RPMI 1640 medium supplemented with 10% FBS, 10 U/mL 
penicillin and 10 μg/mL streptomycin, 2 mM L-Glutamine) and filtered through a 70 μm cell 
strainer to remove any residual tissue fragments.
2.2.13. Preparation of BMDCs—Bone marrow was collected from mouse femurs and 
tibias as reported.44 Erythrocytes were lysed by ACK lysis buffer (Lonza). Bone marrow 
cells were then cultured at 2 × 106/mL in R10 supplemented with 50 μM 2-mercaptoethanol 
and 10 ng/mL each of IL-4 and granulocyte-macrophage-colony stimulating factor (GM-
CSF). The culture was replenished with fresh medium on day 3 without removing old 
medium. On day 6 or 7, BMDCs were harvested and purified with Opti-Prep density 
medium (Sigma) to remove dead cells.
2.2.14. Antigen Presentation Assay in BMDCs—To evaluate the effect of linker 
length on antigen presentation, day 6 BMDCs (3 × 105 cells) were either untreated or treated 
with blank hydrogels (with and without linkers), CSIINFEKL (5 μg/mL), CSIINFEKL 
conjugated to PEG hydrogels via SPDP (short cleavable linker, 5 μg/mL), or CSIINFEKL 
conjugated to PEG hydrogels via PEG(2k)OPSS (longer cleavable linker 5 μg/mL) for 4 h. 
After 4 h incubation, cells were washed with PBS of pH ~7.4 or citrate-phosphate buffer (pH 
3.0) for 3 min on ice to strip off the MHC-I-peptide complex or NP-peptide/H-2Kb complex 
from cell surface. Additionally, cells were reincubated at 37 °C for an additional 20 h 
postwashes and then stained with CD11c-APC and 25-D1.16-PE (anti-SIINFEKL/H-2Kb 
complex) antibodies (eBioscience), followed by flow cytometry analysis on Cyan ADP 
(Dako).
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2.2.15. In Vitro T Cell Proliferation Assay—In vitro CD8+ T cell proliferation was 
done as previously reported.45 Briefly, day 6 BMDCs were dosed with the samples 
described ablove for 24 h at 37 °C. OT-I CD8+ T cells were isolated from OT-I mouse 
spleens using CD8α+ T cell Isolation Kit (Miltenyi Biotec) as per the manufacturer’s 
instructions and labeled with CFSE (5 μM) in PBS with 0.1% FBS for 10 min at 37 °C. 
BMDCs were then incubated with OT-I-CFSE cells in R-10 medium for 72 h at 37 °C. After 
incubation, cells were stained with CD8 and Vα2 antibodies. Division of OT-I cells as 
indicated by dilution of CFSE fluorescence in T cells was examined by flow cytometry.
2.2.16. Immunization Study—All formulations were prepared using low endotoxin 
grade reagents. To confirm the low endotoxin content of vaccines, formulations were 
routinely tested for endotoxin content using Pierce LAL Chromogenic Endotoxin 
Quantitation Kit following instructions. All formulations were prepared 24 h before 
injections, resuspended in an isotonic 9.25% sucrose, and subcutaneously administered in 
the right flank. SIINFEKL was given at a dose of 100 μg, and CpG was injected at a dose of 
20 μg. On day 7, mice were sacrificed, and spleen and draining lymph nodes were harvested. 
All studies were repeated twice, and each experimental arm contained 4–6 mice.
2.2.17. ELISPOT Assay—Frequency of antigen specific IFN-γ producing T cells in 
spleen was evaluated using IFN-γ ELISPOT kit (BD Biosciences). Immobilon-P 
hydrophobic PVDF plates (Millipore) were briefly treated with 35% ethanol, washed 2 times 
with PBS, and coated overnight with anti-mouse IFN-γ antibody at 4 °C. The following day, 
plates were blocked with 200 μL of R-10 medium with for 2 h at room temperature (RT). 
100,000 splenocytes in R-10 medium were plated in each well, with or without restimulation 
with 10 μg/mL of SIINFEKL peptide overnight at 37 °C. Spots were then developed 
following the manufacturer’s instructions.
2.2.18. In Vivo CTL Assay—In vivo CTL assay was performed as previously reported.46 
Briefly, OT-I T cells were isolated from spleen using CD8α+ T cell Isolation Kit (Miltenyi 
Biotec). C57BL/6 mice were injected intravenously with 10,000 OT-I T cells on day −1. On 
day 0, mice were either untreated or immunized subcutaneously with a mixture of soluble 
SIINFEKL and CpG ODN, or NPs-SPDP-CSIINFEKL-CpG, or NPs-PEG(2k)OPSS-
CSIINFEKL-CpG. Fifteen days after vaccination, mice were intravenously injected with 5 × 
106 splenocytes as target cells. To prepare target cells, splenocytes from wild type C57BL/6 
mice were pulsed with SIINFEKL peptide at 1 μg/mL in PBS for 1 h at 37C, washed with 
PBS, and labeled with CSFE at 4 μM in PBS for 10 min at 37 °C (CFSEhi); or non-peptide 
pulsed cells were labeled with CSFE at 0.4 μM in PBS for 1 h at 37 °C (CFSElo). CFSEhi 
and CFSElo cells were mixed at 1:1 ratio to generate target cells for iv injections. On day 16, 
mice were euthanized, splenocytes were isolated, and cells were stained with anti-CD8 and 
Vα2 antibodies. Percentages of CFSEhi and CFSElo were determined with a flow cytometer. 
The ratio of unpulsed to pulsed target cells in the naive (unimmunized) mice defined the 0% 
lysis level. The percent-specific lysis is determined by loss of the antigen-pulsed CFSEhi 
population compared with the unpulsed CFSElo control population using the formula [1 − 
(ratio in naive mouse/ratio in experimental mouse)] × 100.
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3. RESULTS AND DISCUSSION
3.1. Conjugation of CSIINFEKL and CpG to NPs
Pathogen inspired cylinder shaped (80 × 80 × 320 nm) cationic PEG hydrogel NPs were 
fabricated by the PRINT process. It has been established that particles with a net positive 
charge bind to the negatively charged plasma membrane of the cell surface, thus increasing 
cellular uptake, as well as enhancing endosomal escape of cargos.47 Our previous work 
demonstrated that cationic hydrogel particles were able to efficiently deliver siRNA to 
cytosol, resulting in efficient gene silencing.48,49 Furthermore, Fromen et al. demonstrated 
significanlty higher lung and systemic antibody titers when cationic particles were used to 
deliver ovalbumin, as compared to anionic particles.50 Therefore, amine groups on the NP 
surface were used to conjugate cysteine labeled SIINFEKL peptide via reduction sensitive, 
heterobifunctional linkers SPDP or NHS-PEG(2k)OPSS in a two step-process (Figure 1). 
First, the succinimidyl ester of the linker was reacted to the amine groups on the particle, 
forming an amide bond. The excess linker was then removed via centrifugation washes, 
followed by reacting the cysteine labeled adjuvant with the pyridine disulfide ring. Linker 
density was controlled by varying the linker-to-NP ratio (Table S1), in an effort to determine 
maximum linker density while maintaining the positive charge of the nanoparticles. Thus, 
during monoconjugation or dual conjugation of antigenic peptide and CpG, we aimed to 
keep the overall charge of NPs positive (as indicated by zeta potential) to facilitate better 
uptake by APCs and to get possible endosomal escape of cargos. As shown in Table S1, as 
the amount of SPDP charged to the nanoparticle increased from 0.12 mg to 1 mg, the 
conjugated amount of linker increased; however, conjugation efficiency decreased. At the 
highest level of SPDP charged, the ZP of NPs became negative (−21 ± 2 mV) indicating 
almost complete conversion of amine groups and therefore eliminating this formulation from 
further development. The amount of SPDP and NHS-PEG(2k)OPSS used for single 
component conjugation (either peptide or CpG) to modify 1 mg of NPs was 0.24 mg and 6 
mg, respectively, which resulted in positively charge particles.
Particles modified with each linker were then incubated overnight with CSIINFEKL in 
sterile water, resulting in peptide conjugation to the NPs via disulfide exchange, followed by 
incubation with thiol-containing CpG (Figure 1). For co-conjugation reactions, conjugation 
efficiency for peptide and CpG was around 50% and 50–60%, respectively.
Following peptide and CpG modification, NPs remained highly uniform in size and shape as 
visualized by SEM (Figure 2). For all formulations the ZP remained greater than +25 mV 
(Table 2), which is desirable for cytosol delivery of antigens into MHC class I presentation 
pathway. Polydispersity index (PDI) of all sets of nanoparticles was found to be <0.1, which 
indicates monodisperse nanoparticles with homogeneous distribution, and size ranged from 
250 to 280 depending on the surface modification.
3.2. In Vitro Antigen Presentation in BMDCs by Subunit Vaccine
In order for vaccines to generate an efficient CD8+ T cell response, DCs must first 
internalize antigens, process them into 8–12 amino acid peptides, and present them to T cell 
receptors as peptide/MHC-I complexes on the cell surface. T cells recognize MHC-I-peptide 
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complex via T cell receptors and in the presence of other costimulatory signals subsequently 
proliferate. Since antigen presentation is key to developing an efficient T cell response, the 
antigen presentation efficiency of our PRINT NP subunit vaccine was evaluated using an in 
vitro assay. 25-D1.16, an antibody that recognizes SIINFEKL/H-2Kb on antigen presenting 
cells, was used to stain BMDCs treated with various samples to quantify antigen 
presentation. As expected, SIINFEKL peptide binds to H-2Kb on the cell surface directly 
upon 4 h pulsing, while treatment with blank NP-SPDP or NP-PEG(2k)OPSS and washes 
with PBS resulted in minimum staining for MHC-I-peptide complex (Figure 3A). 
Interestingly, cells treated with NP-SPDP-CSIINFEKL or NP-PEG(2k)OPSS-CSIINFEKL 
showed similar surface MHC-I-peptide staining to soluble peptide (Figure 3A and 
Supporting Figure 1I). When unbound peptide or NP-peptide was removed by washes with 
PBS, followed by another 20 h culture at 37 °C, it was observed that both NP-SPDP-
CSIINFEKL and NP-PEG(2k)OPSS-CSIINFEKL led to significantly higher pMHC level 
than that of soluble peptide pulsed BMDCs (Figure 3B and Supporting Figure 1J). On the 
other hand, pMHC complexes on soluble peptide pulsed and washed BMDCs decreased over 
time, suggesting loss of pMHC (Figure 3E). These results indicate that NP conjugation of 
antigenic peptide increases the overall level of cell surface pMHC over time, possibly due to 
enhanced cell uptake of NP-peptides and more efficient delivery of antigenic peptide into the 
class I presentation pathway.
To further examine the capability of delivering antigenic peptide into MHC class I 
presentation pathway by NP-peptide formulations, cells were pulsed with soluble or NP 
conjugated peptides for 4 h, and washed with an acidic citrate-phosphate buffer (pH3.0) for 
3 min to strip off the MHC-I peptide complex from the surface of the BMDCs.51 Cells were 
then incubated for another 20 h at 37 °C allowing for internalized antigens to be represented 
onto cell surface. As shown in Figures 3C and 3F, citrate-phosphate treatment completely 
removed SIINFEKL from pMHC complexes for cells treated with soluble SIINFEKL (down 
to 0.9%), but only partially removed cell bound NP-peptide (down to ~50%) (Supporting 
Figure 1K). This result may be due to the increased binding avidity of NP-peptide to cells as 
a result of the multivalence of peptide on the surface of NPs. As shown in Figure 3D, after 
acidic washes and an additional 20 h incubation, peptide/MHC I staining for NP-SPDP-
CSIINFEKL and NP-PEG(2k)OPSS-CSIINFEKL pulsed cells were 92.7% and 77%, up 
from around 50% (Figure 3G), which was also significantly higher than soluble SIINFEKL 
(6%) (Supporting Figure 1L). During the reincubation period, cells treated with NP 
conjugated peptide had higher staining of pMHC complex, as compared to cells that did not 
go through a reincubation period (Figure 3G), which indicates higher uptake of NP and 
presentation of antigenic peptide. In conclusion, the conjugation of peptide to PRINT NPs 
via cleavable linkers is able to achieve not only higher but also longer lasting presentation of 
antigenic peptide by BMDCs as compared to soluble peptide.
3.3. In Vitro Proliferation of OT-I T Cells in BMDCs Treated with Subunit Vaccine
Next, we evaluated how cross presentation via BMDCs translated into activation and 
priming of CD8+ T cells. CD8+ T cells derived from OT-I TCR transgenic mice were used to 
evaluate OVA-specific T cell response for NP and soluble vaccine formulations. In this 
study, BMDCs, either untreated or treated with soluble SIINFEKL or NP-SIINFEKLNP 
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conjugated peptides, were incubated with 5-(and 6-) carboxyfluorescein diacetate 
succinimidyl ester (CSFE) labeled OT-I T cells for 3 days. Proliferation of T cells was 
evaluated by flow cytometry. A representative flow cytometry histogram for each group is 
shown in Supporting Figure 2. As shown in Figure 4, BMDCs pulsed with soluble peptide at 
a concentration of 5 μg/mL were able to induce proliferation of cognate CD8+ T cells. In 
comparison, much enhanced T cell proliferation was observed for BMDCs treated with NP 
conjugated peptide, which indicates higher priming and activation of CD8+ T cells. 
CSIINFEKL conjugated to PRINT NPs via the longer cleavable linker resulted in 
approximately 95% of T cell growth, as compared to short cleavable linker (74.5%) and 
soluble peptide (32.6%). This is consistent with the enhanced antigen presentation by NP-
peptide demonstrated above (Figure 4).
3.4. Maturation of BMDCs by CpG ODN Conjugated PEG Hydrogels
It is well-known that activation of naive T cells and development of multiple effector 
functions depends not only on recognition of MHC-I-peptide complex on APCs by TCRs 
but also on a second signal from engagement of costimulation receptors. Concurrent delivery 
of adjuvants has been shown to promote the second signals, further drive clonal expansion of 
naive T cells, and aid in their differentiation into armed effector T cells.17 The CD40 ligand 
and CD28 expressed on T cell surface bind to costimulatory molecules CD40 and CD80 on 
the surface of DCs, respectively. CD40 provides signals for activation, while CD80 provides 
signals for proliferation. The ability of PRINT NPs to deliver CpG ODN to provide 
costimulatory signals was tested in BMDCs. BMDCs were incubated with soluble CpG 
ODN or NP-CpG for 18 h. After incubation, cells were analyzed for expression of CD80 and 
CD40 via flow cytometry. Expressions of costimulatory molecules were presented as a ratio 
of mean fluorescent intensity (MFI) to untreated cells. Treatment with CpG conjugated 
PRINT NPs at 1 μg/mL or 10 μg/mL concentrations induced upregulation of CD40 and 
CD80 on BMDCs as compared to untreated cells, as potently as soluble CpG. Therefore, the 
functionality of CpG is well retained during conjugation to nanoparticles. No upregulation 
of either marker was found when BMDCs were treated with CSIINFEKL conjugated NPs. 
Lack of response indicates the limitation of delivering antigen alone for maturation of 
BMDCs. CD40 and CD80 were both upregulated when CpG ODN were combined with 
antigenic CSIINFEKL peptide either via co-conjugation of CpG ODN and SIINFEKL on a 
single NP or when delivered on separate NPs (NP-CpG + NP-peptide), indicating the helper 
effect of adjuvant in the presence of antigen (Figure 5A,B).
3.5. Induction of IFN-γ Producing SIINFEKL Specific CD8+ T Cells in Mice
After evaluating the efficiency of antigen presentation and maturation of BMDCs as well as 
OT-I T cell proliferation, PRINT NP subunit vaccines were analyzed for their efficacy to 
induce IFN-γ producing antigen specific T cells in mice. Frequency of antigen-specific IFN-
γ producing T cells in spleens of mice 7 days postimmunization was evaluated ex vivo by 
ELISPOT. First we evaluated whether co-conjugation of antigen and adjuvant are necessary 
by vaccinating mice with NP-SPDP-CSIINFEKL + NP-SPDP-CpG and NP-SPDP-
CSIINFEKL-CpG. We found that mice treated with NPs co-conjugated to antigenic peptide 
and CpG induced significantly higher CD8+ T cell response as compared to mice treated 
with separately conjugated NPs (Supporting Figure 3). Similar results were also reported by 
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Schlosser et al. when they coencapsulated TLR ligands CpG or poly I:C and antigen in the 
same delivery system.52 Next we tested both the vaccine formulations for their ability to 
induce IFN-γ producing CD8+ T cells. As shown in Figure 6A, there is a significant 
difference in induction of IFN-γ producing CD8+ T cells when mice were immunized with 
NP-SPDP-CSIINFEKL-CpG and NP-PEG(2k)OPSS-CSIINFEKL-CpG as compared to 
mice receiving a mixture of soluble antigen and adjuvant. Co-conjugation of adjuvant and 
antigen resulted in 10 times higher induction of IFN-γ producing T cells as compared to 
NPs conjugated to antigen alone. IFN-γ producing T cell response was minimum in case of 
negative control-blank PRINT NPs.
Secretion of IFN-γ by antigen-specific CD8+ T cells into culture medium upon 
restimulation over 3 days was also examined by ELISA. Similar to T cell frequency 
analysis, the bulk production of IFN-γ was also significantly higher for mice treated with 
NP formulations with co-conjugated peptide and adjuvant as compared to NP conjugated 
with just antigen, or soluble antigen and adjuvant (Figure 6B), again confirming the 
importance of codelivery of CpG adjuvant for IFN-γ production.
3.6. In Vivo CTL Response in Mice after Immunization with SIINFEKL and CpG Co-
conjugated NPs
Induction of CTLs is critical in generating an antitumor immune response. We evaluated 
PRINT NP subunit vaccines for their ability to induce CTLs through an in vivo CTL assay.46 
Fifteen days after immunizations with mixture of soluble SIINFEKL and soluble CpG or 
NP-SPDP-CSIINFEKL-CpG or NP-PEG(2k)OPSS-CSIINFEKL-CpG, mice were 
adoptively transferred with SIINFEKL pulsed, CSFEhi and control nonpulsed, CSFElo target 
cells. On day 16, peptide pulsed and nonpulsed target cells in mouse spleens were 
differentiated by flow cytometry by two distinct population with high and low CFSE 
fluorescence (R5 and R4, respectively in Figure 7A–D). CSFEhi population was decreased 
for peptide pulsed cells in mice immunized with a mixture of soluble peptide and soluble 
CpG (Figure 7B), NP-SPDP-CSIINFEKL-CpG (Figure 7C), and NP-PEG(2k)OPSS-
CSIINFEKL-CpG (Figure 7D). Moreover, the percentage of OVA specific cell killing was 
90% for mice treated with NP-PEG (2k) OPSS-CSIINFEKL-CpG, which is significantly 
higher than for mice treated with soluble antigen with soluble adjuvant (35%) and NP-
SPDP-CSIINFEKL-CpG ODN (50%) (Figure 7E). Results from these assays reveal that the 
longer linker is more efficient at in vivo target cell killing as compared to short linker.
4. DISCUSSION
Here we have shown (i) successful co-conjugation via reduction sensitive linkers of model 
antigenic peptide-SIINFEKL and CpG ODN to hydrogel NPs; (ii) delivery of CSIINFEKL 
via NPs to DCs that induced cross-presentation of SIINFEKL via MHC-I protein molecules 
and subsequently stimulated in vitro proliferation of OT-I T cells; (iii) delivery of CpG ODN 
via NPs provided ‘adjuvanted’ effect by inducing maturation of DCs as demonstrated by 
upregulation of CD80 and CD40; (iv) codelivery of CSIINFEKL and CpG ODN induced 
IFN-γ producing robust CD8+ T cells; and (v) codelivery of CSIINFEKL and CpG ODN by 
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reduction sensitive hydrogel system elicited potent CTLs that kill antigen specific target 
cells.
Within the past decade PRINT NPs have evolved into a unique delivery platform for various 
agents such as chemotherapeutics, fluorescent dyes, quantum dots, siRNA, and 
proteins.48,53–55 Due to the versatility of the PRINT platform, it has been employed to study 
the impact of various particle parameters in a biological system such as biodistribution of 
intravenously administered NPs as well as lymphatic trafficking of particles after 
intramuscular administration.56,57 Utilizing immunologically inert materials to mimic size, 
shape, and surface functionality of pathogens, PRINT provides an excellent platform to 
engineer subunit vaccines investigating various combinations of antigens and adjuvants to 
tune the immune response.58 Galloway et al. showed enhanced humoral response when mice 
were treated with trivalent influenza protein adsorbed cationic PLGA PRINT particles.59 In 
an effort to induce mucosal immune response, Fromen et al. showed higher antibody titers of 
ovalbumin protein when delivered via intranasal immunization by PRINT hydrogels.50 
Building upon this platform, herein we have presented the first PRINT system to induce 
potent CTL response by codelivering antigenic peptides and CpG ODN through reduction 
sensitive linkers.
Disulfide linkers have been widely used in antibody drug conjugates (ADCs) to allow for 
release of chemotherapeutic drugs in intracellular reductive environment and delivering 
antigenic proteins.60 Swartz lab and Hubbell lab have utilized disulfide chemistry to deliver 
model protein OVA as well as TAA peptide, Trp-2 via nanoparticles for the induction of in 
vivo immune response. They have shown induction of potent effector and memory CD8+ T 
cell responses for the inhibition of tumor growth.61–64 Others have also shown higher 
humoral and cellular response by disulfide conjugated OVA via polymeric 
nanoparticles.26,65 One advantage of this technique is that triggered release of the cargo only 
happens upon cellular internalization, due to the presence of various reductive enzymes in 
the endosome, lysosome, and cytosol. Therefore, employing reduction sensitive linkers to 
conjugate CpG ODN and SIINFEKL to NPs, we were able to deliver CpG, resulting in 
stimulation of TLR-9 and the triggered release of costimulatory molecules to enhance T cell 
activation, while also delivering SIINFEKL, to be cross-presented to the surface of APCs 
(vacuolar pathway).5 More experimental studies are required to understand the mechanism 
of NP uptake, trafficking, and antigen release.
Employing peptide antigens has many advantages including cost-effective, enhanced safety, 
specificity, and stability. Short peptides for MHC-I/HLA binding domains can be readily 
synthesized in large quantities. Using defined peptide epitopes allows for the generation of 
very specific arms of effector T cells without the health risk of inducing autoimmune or 
adverse reactions which may occur in response to whole protein antigens.66 Moreover, 
peptides can be chemically modified to improve their solubility, stability, and antigenicity. In 
our studies, the cysteine modification added to the peptide for conjugation purposes did not 
interfere with MHC I binding to SIINFEKL. However, ensuring that peptide modification 
does not alter MHC binding will need to be investigated for each unique application to 
confirm that the appropriate antigen/peptide is being presented. Clinical application of 
peptide vaccine requires matching of patients’ HLA class I alleles to CTL epitopes to be 
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able to induce T cell response. Multiple strategies, like multivalent peptide cocktail, hybrid 
peptides, and long peptides, have been adopted in recent clinical trials to enhance the 
applicability of peptide vaccines.67 Nanoparticle-based delivery platform with versatility in 
peptide association like ours would be able to help simultaneous delivery of multiple 
antigenic peptides.
Polyethylene glycol (PEG) is extensively used in biomedicine and cosmetics due to its 
biocompatibility. It is widely acknowledged that acrylate-derivatized PEG (PEGDA) 
hydrogels undergo slow degradation in vivo due to either hydrolysis of end group acrylate 
esters or oxidation of the ether backbone.68–70 Making PRINT nanoparticles with 
poly(ethylene glycol) diacrylate (PEGDA) allows us to tune many physicochemical 
parameters. Another important parameter of PRINT hydrogel vaccine design is the positive 
surface charge provided by AEM in the composition. Cationic formulations enhance NP 
cellular internalization and endosomal escape thereby delivering cargo in the reductive 
environment of cytosol.48,49,58 Being able to take advantage of these cellular events should 
favor antigen cross presentation through the classical pathway. Neumann et al. has also 
reported inflammasome activation by cationic charged particles alone, which may 
potentially provide adjuvanticity and contribute to the high potency of our particle 
vaccines.71,72 Additionally, positively charged particles remain trapped at the injection site 
because of collagen fibers and negatively charged proteins (glycosaminoglycans) of 
extracellular matrix (ECM).73 Our previous study suggested that 80 × 80 × 320 nm cationic 
particles have minimal lymphatic drainage.57 Thus, our NP vaccines most likely rely on the 
uptake by tissue resident DCs at the injection site for antigen presentation, such as migratory 
CD103+ DCs in peripheral tissues, a subset of DCs very potent in antigen cross 
presentation.5 These results demonstrate the ability to perform well-controlled mechanistic 
studies to investigate the effect of optimizing PRINT particulate vaccine parameters in terms 
of immune cell targeting, APC uptake/activation, and nanoparticle vaccine efficacy.
5. CONCLUSION
In summary, we have investigated the use of an engineered PEG hydrogel subunit vaccine to 
harness the power of our own immune system to generate CTLs to validate this approach in 
the fight against cancer. We have designed and developed a model platform NP subunit 
vaccine to codeliver antigenic peptide and CpG ODN. These NPs were successfully 
internalized and processed by BMDCs, resulting in BMDC maturation, subsequent cross-
presentation of antigenic peptide, and induction of potent antigen-specific T cells. Taken 
together, results from this study provided a highly specific and effective platform to develop 
vaccines against infectious disease and cancer.
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Figure 1. 
Conjugation of cleavable linkers and cysteine labeled SIINFEKL to PEG hydrogels. PEG 
hydrogels were first modified with cleavable linkers SPDP or NHS-PEG(2k)-OPSS. NP-
linker conjugation was evaluted through the release of pyridine-2-thione after incubation of 
NPs with DTT. Linker modified particles were incubated with CSIINFEKL, and peptide 
conjugation was evaluated through the release of pyridine-2-thione.
Kapadia et al. Page 20
Mol Pharm. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Representative SEM image of 80 × 320 nm PRINT subunit peptide vaccine.
Kapadia et al. Page 21
Mol Pharm. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Enhanced antigen presentation by NP-peptide in BMDCs. BMDCs were treated with 
different formulations for 4 h and washed with PBS (A), and incubated for another 20 h (B), 
or washed with acidic citrate-phosphate buffer (pH3) (C), and incubated for another 20 h 
(D). Representative flow cytometry histogram for each group is shown in panels A to D. The 
numbers in the histograms represent the percentage of CD11c+ dendritic cells that were 
positive for p/MHC I. Quantitative analysis of data (E–G). Results are shown as mean ± SD, 
n = 3. E–G, data were analyzed by two-way ANOVA, Tukey’s post hoc analysis, **p < 0.01, 
***p < 0.001.
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Figure 4. 
T-cell proliferation assay. Peptide conjugated NPs induced higher T cell proliferation as 
compared to soluble peptide. Bone marrow derived dendritic cells (BMDCs) were incubated 
for 4 h with free peptide and nanoparticulate peptide conjugated via short and long cleavable 
linkers. Pulsed BMDCs were then incubated with CFSE-labeled OT-I CD8+ T cells for 3 
days. T cells were surface stained, and proliferation of OT-I T cells was assessed by flow 
cytometry. Percentage of T cell proliferation after treatment with different formulations is 
shown in Figure 5. Results are shown as mean ± SD, n = 3. Data were analyzed by one-way 
ANOVA, Bonferroni post hoc analysis, **p < 0.01, ***p < 0.001.
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Figure 5. 
Upregulation of maturation markers by NP-CpG on BMDCs. BMDCs were treated with 
various samples for 24 h with 1, 4, or 10 μg/mL of CpG. Equivalent amounts of NPs were 
dosed in the case of NP-peptide. NP-SPDP-CSIINFEKL (1) has an equivalent dose of NPs 
to 1 μg/mL particulate CpG, and NP-SPDP-CSIINFEKL (2) has an equivalent dose of NPs 
to 10 μg/mL particulate CpG. The expression of costimulatory molecules was detected by 
flow cytometry analysis of fluorescence labeled CD40 and CD80 antibodies. Ratio of MFI 
from sample to MFI of untreated is plotted in panel A for CD40 and panel B for CD80. 
Results are shown here as mean ± SD, n = 3. Data were analyzed by one-way ANOVA, 
Bonferroni post hoc analysis, ***p < 0.001.
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Figure 6. 
Induction of IFN-γ producing SIINFEKL specific CD8+ T cells in spleen. Mice were 
immunized with various samples containing 100 μg of peptide and/or 20 μg of CpG via sc 
injection in the left flank. One week later, splenocytes were isolated and restimulated with 
SIINFEKL for 20 h for IFN-γ ELISPOT assay (A), or for 72 h for ELISA analysis of 
secreted IFN-γ in medium (B). Results are shown as mean ± SD, n = 4. Data were analyzed 
by one-way ANOVA, Holm–Sidak’s multiple comparison test, *p < 0.05, ***p < 0.001.
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Figure 7. 
In vivo CTL response after vaccination with model peptide hydrogel cancer vaccine. NPs-
PEG(2k)OPSS-CSIINFEKL-CpG is more effective at killing target cells compared to NPs-
SPDP-CSIINFEKL-CpG. Purified OT-I CD8+ T cells were adoptively transferred into 
C57BL/6 mice. Two days later, mice were kept (a) untreated or immunized with either (b) 
soluble SIINFEKL + soluble CpG or (c) NPs-SPDP-CSIINFEKL-CpG or (d) NPs-PEG 
OPSS-CSIINFEKL-CpG. Fifteen days later, CFSE labeled wild type splenocytes (non 
peptide pulsed CFSEhi and peptide pulsed CFSElo, 1:1) were iv transferred into immunized 
mice. After 20 h, splenocytes were isolated and population of target cells was determined by 
flow cytometry. Representative histogram analysis of untreated (A), soluble SIINFEKL + 
soluble CpG (B), NPs-SPDP-CSIINFEKL-CpG (C), and NPs-PEG(2k)OPSS-CSIINFEKL-
CpG (D). Quantitation of specific lysis from flow cytometry data in A–D (E). Results are 
shown here as mean ± SD, n = 4. Data were analyzed by one-way anova, Holm-Sidak’s 
multiple comparison test, *p < 0.05, ** p < 0.01, *** p < 0.001.
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Table 1
Gradient Method for HPLC Run
time, min
% of mobile phase
flow rate (mL/min)A B
0 100 0 2
5 100 0 2
25 5 95 2
28 5 95 2
30 100 0 2
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